Seller record · Telehealth service

TRYM Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The answers and the home page refer only to partnered pharmacies. 2 more criteria also fail; see the table below.

At a glance

TRYM HealthTelehealth service

5/8criteria passed

Price: Compounded semaglutide plans from $3.20 a day; tirzepatide from $4.20 a day
Sells: compounded semaglutide, compounded tirzepatide, NAD+, and 2 more
FDA letters: 1 on file

Visit TRYM Health See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A subscription platform selling compounded semaglutide and tirzepatide in multi-dose vials, plus NAD+, sermorelin and glutathione, priced by the day, with a provider's review after the buyer registers, completes an intake form and pays. An FDA warning letter from September 2025 names the company.

Operating entity TRYM Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	TRYM Health's website; TRYM Health's FAQ
S2	Prescription gating	PASS	TRYM Health's website; TRYM Health's FAQ
S3	Pharmacy identification	FAIL	TRYM Health's FAQ; TRYM Health's website
S4	Compounding disclosure	PASS	TRYM Health's services page; TRYM Health's website
S5	Analytical documentation	FAIL	TRYM Health's services page; TRYM Health's FAQ; TRYM Health's refunds page
S6	Business address	FAIL	TRYM Health's contact page; TRYM Health's privacy policy; TRYM Health's FAQ
S7	Price disclosure	PASS	TRYM Health's services page
S8	Enforcement status	PASS	FDA's website; FDA warning letter 716699

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSEach order is matched with a partnered provider for review before it is dispatched, and orders that fail that review are canceled and refunded. No provider is named.Source: TRYM Health's website; TRYM Health's FAQ.

S2PASSThe steps are making an account and completing the registration intake form, then payment, then a provider's review, and the answers say a buyer fills out the intake form first and chooses a plan only if qualified.Source: TRYM Health's website; TRYM Health's FAQ.

S3FAILNo filling pharmacy is named. The answers and the home page refer only to partnered pharmacies.Source: TRYM Health's FAQ; TRYM Health's website.

S4PASSThe services page calls each medication compounded, and the footer on every page states that compounded drugs are not FDA-approved medications and have not been evaluated by the FDA for safety, efficacy or quality.Source: TRYM Health's services page; TRYM Health's website.

S5FAILNo certificate of analysis or lot document is published on the services page, in the answers or in the refund policy.Source: TRYM Health's services page; TRYM Health's FAQ; TRYM Health's refunds page.

S6FAILNo postal address appears on the contact page, in the footer, in the answers or in the privacy policy, which names TRYM Health, Inc.; the contact page mentions two offices without giving either address.Source: TRYM Health's contact page; TRYM Health's privacy policy; TRYM Health's FAQ.

S7PASSThe services page prints plans starting as low as $3.20 a day for compounded semaglutide and $4.20 a day for compounded tirzepatide at any dose, $1.95 a day for NAD+ and $2.75 a day for sermorelin and glutathione, shipping included. A sharps container costs $15 and a cooling thermos $25, and the full product list is shown only to account holders.Source: TRYM Health's services page.

S8PASSFDA warning letter 716699, September 2025, names TRYM Health, Inc. doing business as TRYM Health, reviews this website and writes to the support address it prints. It says claims that the compounded semaglutide and tirzepatide are clinically proven and contain the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound are false or misleading. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 716699.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+, sermorelin, glutathione.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione

Enforcement documents on file: 1 warning letter

FDA warning letter 716699, issued September 2025, to TRYM Health, Inc. dba TRYM HealthClaims that its compounded semaglutide and tirzepatide are clinically proven and contain the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound imply the products are the same as approved products, and are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit TRYM Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.